

(a) contacting a first nematode expressing a mutated *Caenorhabditis elegans* SERT (CeSERT) polypeptide, wherein said mutated CeSERT polypeptide has a reduced capacity to take up serotonin relative to wild-type, with said compound;

(b) assaying a defined behavior of said first nematode; and

(c) comparing said defined behavior of said first nematode to the defined behavior of a second nematode not contacted with said compound, wherein a difference in said defined behavior between said first and second nematode indicates that said compound has a secondary target.

B1
Amended

2. (Amended) The method of either claim 1 or 12, wherein steps (a) to (c) are repeated using first and second nematodes selected from a panel of nematodes expressing mutant CeSERT polypeptides, wherein said mutant CeSERT polypeptides differ from said mutated CeSERT polypeptide of step (a).

CONCLUSION

Applicants submit that pending claims 1-12 are in condition for allowance, and such action is respectfully requested.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

January 20, 2003

Kristina Bieker-Brady

Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

\\Clark-w2k1\documents\01997\01997.525002 Reply to 12.24.02 Office Communication.wpd